This thrombocytosis (defined as circulating thrombocytes of more than 450.000/mm3) is determined by aberrant paracrine signaling via a high circulating level of interleukin 6 (a by-product of the tumor microenvironment) and thrombopoietin (produced by the liver) [65]. This evidence concerns the gene IL6 and thrombocytosis disease.